Close Menu

NEW YORK – Phio Pharmaceuticals and AgonOx on Monday said they will collaborate on the development of T cell-based immunotherapies by combining Phio's lead product, the self-delivering RNAi compound PH-762, and AgonOx's "double positive" tumor-infiltrating lymphocyte (TIL) technology.

In preclinical studies, the companies have shown that treating "double positive" CD8 TILs with PH-762 improves their ability to kill tumor cells. Phio and AgonOx are planning to advance PH-762-treated "double positive" TILs into a clinical study and begin enrollment later this year.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Sponsored by

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.